Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity

被引:19
|
作者
Lundstrom, K
Hawcock, AB
Vargas, A
Ward, P
Thomas, P
Naylor, A
机构
[1] GLAXO WELLCOME RES & DEV LTD,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND
[2] GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND
关键词
Semliki Forest virus system; tachykinin NK1 receptor; mutagenesis; site-directed; binding assays; functional coupling;
D O I
10.1016/S0014-2999(97)01226-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Molecular modelling and site-directed mutagenesis were used to identify eleven amino acid residues which may be involved in antagonist binding of the human tachykinin NK1 receptor. Recombinant receptors were expressed in mammalian cells using the Semliki Forest virus system. Wild type and mutant receptors showed similar expression levels in BHK and CHO cells, verified by metabolic labelling Binding affinities were determined for a variety of tachykinin NK1 receptor antagonists in SFV-infected CHO cells. The binding affinity for GR203040, CP 99,994 and CP 96,345 was significantly reduced by mutant Q165A. The mutant F268A significantly reduced the affinity for GR203040 and CP 99,994 and the mutant H197A had reduced affinity for CP 96,345. All antagonists seemed to bind in a similar region of the receptor, but do not all rely on the same binding site interactions. Functional coupling to G-proteins was assayed by intracellular Ca2+ release in SFV-infected CHO cells. The wild type receptor and all mutants except A162L and F268A responded to substance P stimulation. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 50 条
  • [22] SCH 206272:: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist
    Anthes, JC
    Chapman, RW
    Richard, C
    Eckel, S
    Corboz, M
    Hey, JA
    Fernandez, X
    Greenfeder, S
    McLeod, R
    Sehring, S
    Rizzo, C
    Crawley, Y
    Shih, NY
    Piwinski, J
    Reichard, G
    Ting, P
    Carruthers, N
    Cuss, FM
    Billah, M
    Kreutner, W
    Egan, RW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (02) : 191 - 202
  • [23] In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK1 and NK2 receptor antagonist
    Robineau, P
    Lonchampt, M
    Kucharczyk, N
    Krause, JE
    Regoli, D
    Fauchere, JL
    Prost, JF
    Canet, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (2-3) : 677 - 684
  • [24] Gut feelings about tachykinin NK1 receptor antagonists
    Laird, J
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) : 169 - 169
  • [25] Design, synthesis, and SAR of tachykinin antagonists:: Modulation of balance in NK1/NK2 receptor antagonist activity
    Albert, JS
    Aharony, D
    Andisik, D
    Barthlow, H
    Bernstein, PR
    Bialecki, RA
    Dedinas, R
    Dembofsky, BT
    Hill, D
    Kirkland, K
    Koether, GM
    Kosmider, BJ
    Ohnmacht, C
    Palmer, W
    Potts, W
    Rumsey, W
    Shen, LH
    Shenvi, A
    Sherwood, S
    Warwick, PJ
    Russell, K
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) : 3972 - 3983
  • [26] Polymorphic behavior of an NK1 receptor antagonist
    Wang, Y
    Wenslow, RM
    McCauley, JA
    Crocker, LS
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) : 147 - 159
  • [27] The tachykinin NK1 receptor in the brain:: pharmacology and putative functions
    Saria, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 375 (1-3) : 51 - 60
  • [28] Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist
    Ballard, TM
    Sänger, S
    Higgins, GA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 412 (03) : 255 - 264
  • [29] Evaluation of PD154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain
    Gonzalez, M
    Field, MJ
    Holloman, EF
    Hughes, J
    Oles, RJ
    Singh, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 344 (2-3) : 115 - 120
  • [30] PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL NK1 RECEPTOR LIGAND NETUPITANT AT HUMAN TACHYKININ RECEPTORS
    Campi, B.
    Camarda, V.
    Pietra, C.
    Cantoreggi, S.
    Calo, G.
    NEUROPEPTIDES, 2010, 44 (06) : 539 - 540